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Detection of donor-speciﬁc anti-HLA antibodies (DSA) has been associated with graft rejection in all forms of
transplantation. The mechanism by which DSA increase the risk of graft failure remains unclear. We hy-
pothesized that complement-binding DSA are associated with engraftment failure in hematopoietic stem cell
transplantation (HSCT) and analyzed 122 haploidentical transplant recipients tested prospectively for DSA.
Retrospective analysis to detect C1q binding DSA (C1qþDSA) was performed on 22 allosensitized recipients.
Twenty-two of 122 patients (18%) had DSA, 19 of which were women (86%). Seven patients with DSA (32%)
rejected the graft. Median DSA level at transplant for patients who failed to engraft was 10,055 mean ﬂuo-
rescence intensity (MFI) versus 2065 MFI for those who engrafted (P ¼ .007). Nine patients with DSA were
C1q positive in the initial samples with median DSA levels of 15,279 MFI (range, 1554 to 28,615), compared
with 7 C1q-negative patients with median DSA levels of 2471 MFI (range, 665 to 12,254) (P ¼ .016). Of
9 patients who were C1q positive in the initial samples, 5 patients remained C1q positive at time of transplant
(all with high DSA levels [median, 15,279; range, 6487 to 22,944]) and experienced engraftment failure,
whereas 4 patients became C1q negative pretransplant and all engrafted the donor cells (P ¼ .008).
In conclusion, patients with high DSA levels (>5000 MFI) and complement-binding DSA antibodies (C1q
positive) appear to be at much higher risk of primary graft failure. The presence of C1qþDSA should be
assessed in allosensitized patients before HSCT. Reduction of C1qþDSA levels might prevent engraftment
failure in HSCT.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allosensitization is a common problem in both solid or-
gan and hematopoietic stem cell transplantation (HSCT)
[1,2]. Approximately 50% of all patients requiring a transplant
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ty for Blood and Marrow Transplantation.antibodies, and up to 30% of patients might have donor-
speciﬁc anti-HLA antibodies (DSA) that pose a threat to or-
gan rejection or graft failure (GF) in HSCT [3,4]. Our group
initially showed that DSA are associated with primary GF in
HSCT with mismatched donors [5,6]. Although a clear asso-
ciation between DSA and GF in HSCT has been subsequently
demonstrated [7-11], the mechanism by which DSA may
cause GF in HSCT remains unclear.
Activation of the complement cascade has been shown in
allosensitized recipients of solid organ transplantation and
has been suspected in animal models of HSCT [12,13]. The
classical pathway of the complement cascade is activated
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tiates activation of other complement components, resulting
in the formation of membrane attack complex, which in turn
causes cell lysis with apoptosis and clearance of the targeted
cells [14,15].
In HSCT, DSA that target donor HLA antigens present on
the surface of hematopoietic progenitor cells, and anti-
geneantibody complexes that may bind to C1q, activate the
complement cascade and cause destruction of the donor
cells, resulting in allograft rejection. C1q assay was devel-
oped to detect C1q binding (complement binding or com-
plement ﬁxing DSA) in allosensitized recipients of solid
organ transplants [16,17]; however, whether complement
cascade activation represents a mechanism that mediates
graft rejection in HSCT remains unclear. Here we hypothe-
sized that complement-binding DSA might be associated
with primary GF in HSCT and assessed the joint impact of
DSA and C1q activation in a cohort of allosensitized
recipients.
METHODS
Patients
One hundred twenty-two consecutive patients received HSCT at the
University of Texas MD Anderson Cancer Center between September 2005
and September 2013, 21 (17%) with T cell depletion (CD34þ selection) and
101 (83%) using a Tcellereplete bonemarrowgraft and post-transplantation
cyclophosphamide, tacrolimus, and mycophenolate for graft-versus-host
disease prevention, as previously reported by us [18,19]. Patients were
tested prospectively between 2008 and 2013, whereas a small number of
patients (treated before 2008) were tested retrospectively for the presence
of DSA in pretransplant specimens. Retrospective C1q assay was performed
on banked serum samples in all patients with DSA.
DSA Testing
Pretransplant sera of all patients were tested prospectively for anti-HLA
class I and class II antibodies using multianalyte bead assays performed on
the Luminex platform (Luminex, Austin, TX), including LABScreen PRA,
LABScreenmixedmethods for screening. The binding level of donor-speciﬁc
antibody was determined by the LABScreen single-antigen bead assay (One
Lambda, part of Thermo Fisher Scientiﬁc, Canoga Park, CA) per manufac-
turer’s instructions, and results were expressed as mean ﬂuorescence
intensity (MFI). Brieﬂy, 5 mL of mixed beads, HLA class I and class II single-
antigen beads, were added to 20 mL of sample serum and incubated for 30
minutes at room temperature in the darkwith gentle shaking. After washing
with wash buffer 3 times, 100 mL of goat anti-human IgG secondary antibody
conjugated with R-phycoerythrin was added, and the samples were incu-
bated in the dark for 30 minutes at room temperature. After washing
3 times, the samples were read on a Luminex-based LABScan 100 ﬂow
analyzer. Antibody speciﬁcity and binding level were analyzed and deter-
mined through HLA Visual or HLA Fusion software from the manufacturer.
C1q Assay
Complement-binding antibodies were detected retrospectively for pa-
tients with DSA using the C1q assay as reported by Chen et al. [16]. The
complement component (C1q) bound by the antigeneantibody complex
was detected with an R-phycoerythrinelabeled anti-C1q antibody. Fluo-
rescence intensity was measured using a Luminex-based LABScan 100 ﬂow
analyzer. DSA speciﬁcity and binding level were determined by the
C1qScreen assay per manufacturer’s instructions (One Lambda). Brieﬂy, 5 mL
of human C1q and 5 mL of HLA class I and class II single-antigen beads were
added to 5 mL of heat-inactivated sample serum and incubated for 20 mi-
nutes in the dark at room temperature, followed by adding 5 mL of R-phy-
coerythrinelabeled anti-C1q antibody and incubation for 20 minutes in the
dark at room temperature. The samples were analyzed and the C1q binding
speciﬁcity determined.
Treatment of Patients with DSA before Transplantation
Twelve patients with DSA (55%) received desensitization treatment
before transplant with alternate day plasma exchange 3 (1 to 1.5 plasma
volume), replaced with either fresh frozen plasma or with albumin, starting
1 week before admission for transplantation/beginning of conditioning
chemotherapy, followed by 1 dose of 375 mg/m2 rituximab (Rituxan) the
next day after completion of plasma exchange, followed 1 day later by 1 dose
of intravenous immunoglobulin (IVIG) 1 g/kg 1 (PE/R/IVIG) [5]. In addition,5 patients received a buffy coat infusion on day 1, prepared from the same
haploidentical donor.Buffy Coat Preparation
Bone marrow stem cell donors underwent 2 autologous phlebotomies
within 30 days of the scheduled bone marrow harvest. On both occasions,
500 mL of whole blood was collected in citrate-phosphate-dextrose adenine
collection bags. The buffy coat was prepared from the second phlebotomy
performed 2 days before marrow stem cell infusion (day 2). The second
autologous whole blood unit was separated by centrifugationwithin 8 hours
of collection into packed RBCs and plasma containing the buffy coat layer.
The plasma component then underwent a second centrifugation to separate
the buffy coat. The ﬁnal RBCs and buffy coat volume consisted of approxi-
mately 40 to 50mL, whichwas then cross-matched, irradiated, and ready for
infusion to the patient. All donors consented and were tested for infectious
disease markers in accordance with the current American Association of
Blood Banks and US Food and Drug Administration guidelines.Statistical Methods
Summary statistics were computed for all patients and within speciﬁc
subgroups. Categorical variables were summarized by frequencies and
percentages and their associations assessed using either Fisher’s exact test
[20] or the Fisher-Freeman-Halton test [21]. Continuous variables were
summarized by median and range (minimum, maximum) and their asso-
ciations with categorical variables assessed using the Wilcoxon rank sum
test [22]. GF was deﬁned as the patient not engrafting, experiencing delayed
engraftment beyond day 28 post-transplant, or neutrophil recovery with
autologous reconstitution veriﬁed by chimerism. Associations between GF
and patient covariates were assessed by ﬁtting a Bayesian logistic regression
model for the probability of GF as a function of numerical DSA value within
each C1q status subgroup, type of pretransplant T cell depletion (T cell
depleted versus T cell replete), age, gender, race, and diagnosis. A similar
model, including only DSAvalue within each C1q status as covariates, was ﬁt
in the subgroup of 17 patients who received T cell depletion. In each ﬁtted
Bayesian model, the expression Pr(b > 0 j Data) is the posterior probability
that the coefﬁcient of the associated variable is positive. Values either >.99
or <.01 may be interpreted as highly signiﬁcant, values ranging from .95 to
.99 or .01 to .05 may be interpreted as signiﬁcant, and values ranging from
.90 to .94 or .06 to .10 may be interpreted as moderately signiﬁcant.
Overall survival (OS) was computed from date of HSCT to date of last
known vital sign for those groups categorized at or before HSCT date. For GF
status, which was assessed after the date of stem cell infusion, OS was
determined using a landmark analysis where 1 month after HSCT was
deﬁned as the landmark time. Patients who did not experience engraftment
within 1 month of HSCT were categorized as GF. Patients alive at the last
follow-up date were administratively censored. Time to engraftment was
computed from date of HSCT to date of engraftment or administratively
censoring at either last follow-up date or date of delayed engraftment. The
Kaplan-Meier method [23] was used to estimate unadjusted distributions of
OS, and time to engraftment and the log-rank test [24] was used to assess
differences between groups, where appropriate.
All statistical analyses were performed using SAS 9.3 for Windows
(Copyright  2011 by SAS Institute Inc., Cary, NC). All statistical tests used a
signiﬁcance level of 5%. No adjustments for multiple testing were made.RESULTS
Baseline Characteristics of Transplant Recipients
Of 122 patients who received a haploidentical transplant
andwere tested for anti-HLA antibodies, 22 (18%) were found
to have DSA in the initial samples. The median DSA level in
the initial sample for all patients was 6040 MFI (range, 85 to
28,615), whereas the median DSA level at transplant was
4667 MFI (range, 614 to 22,944). Patient characteristics
overall and by DSA status are summarized in Table 1. From
the entire cohort of patients, 19 of 58 female patients (33%)
were allosensitized versus 3 of 64 male patients (5%; P <
.0001). Similarly, a much higher percentage of DSA-positive
patients were women (86%) compared with those who
were DSA negative (39%; P < .0001). In addition, women had
higher DSA levels than men: median 7858 MFI versus 864
MFI, respectively (P ¼ .021). No other signiﬁcant differences
were found between the DSA-positive and -negative groups
except that a signiﬁcantly higher percentage of patients with
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myelodysplastic syndrome (76% versus 55%).Impact of DSA and C1q Status on Engraftment
GF and DSA status were initially assessed for all patients
(Table 1). Two patients died early and were not evaluated for
GF. Overall, 11 of 120 assessable patients (9%) experienced GF.
Consistent with what we previously reported [5], a signiﬁ-
cantly higher proportion of DSA-positive patients in this
study experienced GF (7/22, 32%) compared with DSA-
negative patients (4/98, 4%; P < .001). In patients who were
allosensitized, all GF events occurred in those with DSA
levels > 5000 MFI at transplant (P ¼ .004, Table 2). The
median DSA level at transplant for patients who engrafted
versus those who rejected the graft was 2065 MFI versus
10,055 MFI, respectively (P ¼ .007).
Time to engraftment was assessed by DSA status
(Figure 1A) as well as by C1q (Figure 1B). The median time toTable 1
Patient Characteristics and Outcomes Overall and by DSA Status
Measure All (N ¼ 122)
Gender, n (%)
Male 64 (52)
Female 58 (48)
Age at transplant, yr
Median 42.0
Range 18.0-67.0
Race/ethnicity, n (%)
White 52 (43)
Black 29 (24)
Hispanic 2 (2)
Other 39 (32)
Diagnosis, n (%)
AML/MDS 71 (59)
ALL 14 (12)
CLL/lymphoma 18 (15)
CML/MPD 15 (12)
Other 3 (2)
Missing 1
Transplant type, n (%)
T cell depleted 21 (17)
T cell replete 101 (83)
C1q status at transplant, n (%) (DSA patients only)
Positive 5 (24)
Negative 16 (76)
Missing 1
Treatment, n (%) (DSA patients only)
None 10 (45)
Desensitization alone 7 (32)
Desensitization þ buffy coat 5 (23)
Number of loci having antibodies (DSA patients only)
1 12 (60)
>1 8 (40)
Not assessable 2
Outcomes
GF, n (%)
Yes 11 (9)
No 109 (91)
Early death 2
OS, mo
Median 14.1
95% conﬁdence interval 9.1-25.6
ALL/MDS indicates acute myelogenous leukemia/myelodysplastic syndrome; ALL,
chronic myelogenous leukemia; MPD, myeloproliferative disorder; NE, not estima
* Fisher’s exact test.
y Wilcoxon rank sum test.
z Fisher-Freeman-Halton test.
x Log-rank test.engraftment for all patients was 18 days. A signiﬁcant dif-
ference in time to engraftment was noted for DSA status (P ¼
.004). Although the difference in median time to engraft-
ment for DSA-positive patients compared with DSA-negative
patients was very small (19 days versus 18 days), the per-
centage of patients experiencing engraftment was lower for
DSA-positive patients (68%) compared with DSA-negative
patients (96%). Within allosensitized patients, the median
time to engraftment for those with DSA levels  5000 MFI
was 16 days; however, for patients with DSA levels > 5000
MFI, the median time to engraftment was not reached
because less than 50% of those patients engrafted.Joint Impact of DSA and C1q Status on Engraftment for
Patients with DSA
All patients with DSA and available serumwere tested for
the presence of C1q, both in the initial serum samples and
after receiving treatment/before infusion of stem cells fromDSA
Yes (n ¼ 22) No (n ¼ 100) P*
3 (14) 61 (61) <.0001
19 (86) 39 (39)
40.5 43.0 .64y
20.0-63.0 18.0-67.0
8 (36) 44 (44) .48z
8 (36) 21 (21)
0 2 (2)
6 (27) 33 (33)
16 (76) 55 (55) .0211z
1 (5) 13 (13)
0 18 (18)
2 (10) 13 (13)
2 (10) 1 (1)
1 0
5 (23) 16 (16) .53
17 (77) 84 (84)
5 (24) d d
16 (76) d
1 d
10 (45) d d
7 (32) d
5 (23) d
12 (60) d d
8 (40) d
2 d
7 (32) 4 (4) .0006
15 (68) 94 (96)
0 2
.14x
8.9 16.0
3.8-24.7 9.6-NE
acute lymphoblastic leukemia; CLL, chronic lymphoblastic leukemia; CML,
ted.
Table 2
Associations between GF, C1q Status, and Treatment
Covariate GF Fisher’s
Exact
Test P
Yes
(n ¼ 7)
No
(n ¼ 15)
C1q at transplant, n (%) .0003
Positive 5 (100) 0
Negative 1 (6) 15 (94)
Nonassessable 1 0
DSA levels at transplant, n (%) .0039
>5000 7 (64) 4 (36)
5000 0 11 (100)
Treatment, n (%) .14
None 3 (30) 7 (70)
Desensitization alone 4 (57) 3 (43)
Desensitizationwith buffy coat 0 5 (100)
GF indicates graft failure; DSA, donor-speciﬁc anti-HLA antibodies.
Figure 1. Probability of engraftment in patients by DSA status (A) and C1q
status (B).
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testing in the initial samples, and 21 patients (95%) had
serum available in the subsequent samples for C1q evalua-
tion. At the time of initial testing, 9 of 16 patients (56%) were
C1q-positive patients, with a median DSA level of 15,279 MFI
(range, 1554 to 28,615), compared with 7 C1q-negative pa-
tients, who had a median DSA level of 2471 MFI (range, 664
to 12,254) (P ¼ .016).
At the time of transplant, 5 of 9 patients who were pos-
itive at initial testing remained C1q positive. All 5 of these
C1q-positive patients had DSA levels > 5000 MFI (median,
15,279; range, 6487 to 22,944), and all experienced GF.
Conversely, all 4 patients whowere initially C1q positive and
became C1q negative at transplant experienced engraftment
of donor cells. A signiﬁcantly higher percentage of C1q-
positive patients experienced GF compared with C1q-
negative patients (P < .001, Table 2). The median time to
engraftment for C1q-negative patients was 18 days; how-
ever, for C1q-positive patients the median time to engraft-
ment was not reached because less than 50% of those
patients engrafted.
As shown by Figure 3, the distributions of numerical DSA
value in the C1q-positive and C1q-negative patients were
very different, with on average much higher DSA values in
the C1q-positive patients. Because of this strong association
between DSA and C1q status, to assess effects of these vari-
ables and other patient covariates on the probability of GF,
Prob(GF), a Bayesian logistic regression model was ﬁt
including terms for DSA within each C1q status subgroup,
type of pretransplant Tcell depletion (Tcell depleted versus T
cell replete with post-transplant cyclophosphamide), age,
gender, race, and diagnosis. The ﬁtted model, summarized in
Table 3, shows that higher DSA was signiﬁcantly associated
with a larger Prob(GF) in C1q-positive patients, with Pr(b> 0
j Data) ¼ .95, and was moderately signiﬁcantly associated
with a smaller Prob(GF) in C1q-negative patients. No other
covariates had a signiﬁcant effect on Prob(GF).
The joint effect of DSA and C1q status was assessed
similarly in the subgroup of 17 DSA-positive patients who
received T cell replete graft but without additional covariates
included in the model because of the small subsample size.
The ﬁtted model, summarized in Table 4, shows that the
signiﬁcant association of higher DSA with a larger Prob(GF)
in C1q-positive patients persisted in this subgroup, with Pr(b
> 0 j Data)¼ .98. It thus appears that the deleterious effect of
higher DSA in C1q-positive patients may be general and not
dependent on type of graft-versus-host disease prophylaxis.Treatment of Patients with DSA and Transplant
Outcomes
We initially adopted a multimodality treatment strategy
similar to that used in solid organ transplantation in an
attempt to decrease antibody levels before the beginning of
transplant conditioning chemotherapy and achieve engraft-
ment in allosensitized recipients using the PE/R/IVIG
regimen [5], as described inMethods. Because this treatment
appeared to be only partially effective, we added infusion of
an irradiated buffy coat prepared 24 to 48 hours in advance
from a unit of donor peripheral blood and infused 1 day
before the infusion of stem cells, hypothesizing that infusion
of HLA antigens from the same donor would clear C1qþDSA
and promote engraftment of donor cells.
Of the 22 patients with DSA, 10 (45%) received no
desensitization treatment, whereas 12 patients (55%)
received desensitization treatment with PE/R/IVIG alone (n¼
7) or the same treatment plus the addition of buffy coat
infused on day1 (n¼ 5). In the untreated group, 2 of 6 C1q-
positive patients remained C1q positive at transplant and
experienced GF (1 patient had no serum left for testing, had
high DSA levels of 11,283 MFI in the initial sample, and
experienced GF), 5 of 7 patients in the desensitization alone
group were C1q positive in initial samples, and 3 remained
positive at transplant, and all experienced engraftment fail-
ure. In the buffy coat group, 2 of 5 patients were C1q positive,
and both became negative before stem cell infusion and
achieved engraftment of donor cells. In summary, all 5 pa-
tients who remain C1q positive after treatment/before
transplant experienced engraftment failure, whereas all 4
Figure 3. Histograms of DSA distributions within the C1q-positive (þ) and
C1q-negative () subgroups.
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transplant engrafted the donor cells. Interestingly, we did not
observe signiﬁcant changes in antibody levels during treat-
ment including with buffy coat before the stem cell infusion
(data not shown). These results suggested that reduction to
nonecomplement binding DSA should be the goal of treat-
ment rather than clearing of the nonecomplement binding
DSA, which appear to clear more slowly in the immediate
post-transplant period and became undetectable in all pa-
tients within the ﬁrst few weeks after transplant, similar to
prior experience [25].
Assessment of OS
OS was assessed by DSA and C1q combined status (data
not shown), GF status (using a landmark analysis, Figure 2),
and by treatment group for patients with DSA (Supplemental
Figure 1). The median OS 1 month post-transplant for pa-
tients who experienced GF was shorter compared with those
who did not experience GF (5.3 months versus 17.1 months).
Finally, median OS for DSA patients who did not receive
treatment was 5.3 months compared with 8.9 months for
DSA patients receiving desensitization alone and 13.4
months for patients receiving desensitization plus buffy coat.
DISCUSSION
We hypothesized that complement activation plays an
important role in the development of GF in HSCT and
investigated the role of C1q, the ﬁrst component of the
classical complement pathway, in a cohort of allosensitized
HSCT recipients. Although demonstrated in a limited number
of patients, a high association between complement binding
DSA and engraftment was observed. Previous work by Chen
et al. [16] showed no complete correlation between C1q
binding antibodies and IgG MFI levels, indicating an effect
associated with the ability of DSA to ﬁx complement. These
results also suggest a complement-dependent cytotoxicity
rather than an antibody-dependent cell mediated cytotox-
icity mechanism to primary GF in transplantation; however,
potentiation by antibody-dependent cell mediated cytotox-
icity cannot be excluded [13,26] and implies that at least a
reduction of DSA to nonecomplement binding levels before
transplant is of paramount importance in achieving
engraftment in these highly allosensitized individuals.
As we have previously shown [6], a high-risk population
is middle-aged multiparous women who become allosensi-
tized through exposure to foreign HLA antigens duringFigure 2. Overall survival by GF status (landmark analysis).pregnancy. Updated results in this larger series of hap-
loidentical transplant recipients conﬁrmed those ﬁndings. A
third of all female patients requiring a haploidentical trans-
plant had DSA, and the great majority of allosensitized re-
cipients were women (90%) with high MFI levels. Male
recipients had much lower MFI levels, and none was C1q
positive, suggesting a much lower risk population. Although
GF can occur with lower MFI levels, it is evident now that
female recipients are at much higher risk to become allo-
sensitized, with pregnancy producing a much higher risk for
allosensitization than transfusion of blood products.
This is the ﬁrst study to examine the association between
complement binding DSA and risk of primary GF in patients
with HSCT. We observed signiﬁcantly higher probability of
GF in patients with higher DSA levels and C1q positivity
(Table 3, Figure 4), and this effect also was seen in the sub-
group of 17 T cellereplete haploidentical transplant patients.
Our results indicate that presence of a positive C1q assay is
associated with engraftment failure in patients with higher
DSA and the goal of treatment should be clearing of the
complement ﬁxing antibodies before infusion of stem cells. A
positive C1q assay was signiﬁcantly associated with highly
allosensitized patients (high DSA levels), suggesting thatTable 3
Fitted Bayesian Logistic Regression Model Assessing Covariate Effects on the
Probability of GF in 21 DSA-Positive Patients for Whom C1Q Status Was
Evaluated in which 6 Patients Suffered GF
Variable Posterior Quantities
Mean
of b
SD
of b
95%
Credible
Interval
Pr(b >
0 j Data)
Intercept .408 1.906 4.069 3.302 d
Log(DSA)*[DSAþ/C1qþ] 1.920 1.252 .353 4.502 .95
log(DSA)*[DSAþ/C1q] 1.373 1.005 3.324 .557 .079
T cell depleted type vs.
T cell replete type
.539 1.704 3.826 2.873 .382
Age at HSCT .008 .075 .132 .164 .564
Male vs. female .997 1.682 4.306 2.315 .280
White vs. other 1.711 1.539 1.351 4.661 .872
AML/MDS diagnosis vs. other .755 1.585 2.176 3.969 .679
SD indicates standard deviation.
Table 4
Fitted Bayesian Logistic Regression Model Assessing the Probability of GF in
the Subgroup of 17 DSA-Positive Patients Who Received T CelleReplete
Grafts
Variable Posterior Quantities
Mean
of b
SD
of b
95%
Credible
Interval
Pr(b >
0 j Data)
Intercept .293 1.829 3.863 3.336 d
log(DSA)*DSAþ/C1qþ 1.845 1.170 .240 4.212 .98
log(DSA)*DSAþ/C1q .737 .620 1.956 .475 .113
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apoptosis of hematopoietic progenitor cells [27]. Although
the number of patients with complement binding DSA was
relatively small, the high risk of GF seen in patients who had
high DSA levels and were C1q positive suggests that this is a
very high-risk condition that should be avoided. Upfront
testing of C1q in patients with DSA is necessary, as our data
suggest that clearance of C1q is needed to obtain engraft-
ment of donor cells. A 2-step cost-effective approach may be
to screen for DSA patients with mismatched transplants and
test for C1q patients who are allosensitized. Half of the pa-
tients with high DSA levels (>5000 MFI) tested negative for
the C1q assay, and their risk for rejection was much lower. In
fact, only 1 patient in this category rejected the graft (MFI of
6265.78). It remains unclear if complement pathway gets
activated in these patients or not, and future studies should
attempt to elucidate this aspect.
In contrast with reports from a different institution
[28,29], our experience suggested that treatment with PE/R/
IVIG is only partially effective in treating allosensitized re-
cipients of HSCT, similar to the experience reported in solid
organ transplantation [30,31]. A novel approach developedFigure 4. Diagram illustrating the decrease in rate of engraftment for all pa-
tients based on DSA and C1q status identiﬁed at the time of initial testing.by our group has focused on blocking the DSA with HLA
antigens from the donor using a buffy coat prepared from the
donor cells (using HLA antigen of the donor). Peripheral
blood mononuclear cells express both HLA class I and II on
the cell surface and seem to be an ideal source for HLA an-
tigens, as compared with RBCs or platelets, which may ex-
press only partially HLA antigens limited to mostly HLA class
I [32]. In our experience, all patients with complement
binding antibodies and high DSA levels (>5000 MFI) were
broadly allosensitized against both HLA class I and class II
antigens; thus, a blood product capable of reliably binding all
antigens is needed.
Our results are in line with experience from solid organ
transplantation [33]. Taken together, these data suggest that
complement-mediated rejection plays a major role in
antibody-mediated graft rejection and that the presence of
C1q binding DSA should be tested routinely along with DSA
levels before transplant. In addition, it appears that C1q
negativity should be the goal of treatment, at least in C1q-
positive patients, and high DSA levels may not clear right
away from circulation. Infusion of donor HLA antigens in the
form of a buffy coat is a promising approach for the treat-
ment of C1q-positive patients and should be further explored
in prospective clinical trials.
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